Zoekresultaten - 5 results

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.

healthy) received a third dose of BNT162 b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 ...

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.

Viral Biomarkers BNT162 Vaccine COVID-19 Vaccines Humans Immunity, Humoral Immunization Schedule Immunization, Secondary Immunogenicity, Vaccine Neoplasms Prospective Studies Risk Factors Time Factors ...

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.

5 (2021) Keywords: Antineoplastic Agents BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunity, Humoral Neoplasms Prospective Studies RNA, Messenger SARS-CoV-2 Vaccination Abstract: BACKGROUND: Cancer ...

Vaccine preventable bacterial diseases in Belgium: monitoring of general population immunity and pregnancy vaccination strategies

Publication Type: Dissertation Authors: Raïssa Nadège Caboré Source: VUB, Brussels, Belgium, p.183 (2017) Accession Number: NA Keywords: bacterial diseases Belgium general population immunity ...

Induction of immunity by DNA vaccination: application to influenza and tuberculosis.

Immunity, Cellular Influenza A virus Influenza Vaccines Lymphocyte Activation mice Mice, Inbred BALB C Mice, Inbred C57BL Mycobacterium tuberculosis Nucleoproteins RNA-Binding Proteins Spleen T-Lymphocytes, ...

QR code

QR code for this page URL